Summary of Study ST002923

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001816. The data can be accessed directly via it's Project DOI: 10.21228/M8ZX5S This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002923
Study TitleGut sphingolipid metabolites in infants with atopic dermatitis associated with food allergy - Part 1
Study SummaryFood allergy (FA) may be present in the range of 20–80% in atopic dermatitis (AD). Food sensitization through the skin can cause FA due to damage to the skin barrier, and failure to acquire tolerance to food allergens in the gut can equally cause the development of FA. Gut metabolites can influence the physical gut barrier and intestinal homeostasis. Therefore, it is possible that gut metabolites related to gut immunity play an important role in the development of FA. Sphingolipids are key factors in cell inflammatory response and affect gut epithelial cells and skin barrier integrity and function. FA is associated with a marked decrease in serum sphingolipid levels. However, there are no reports of FA-associated gut sphingolipid metabolites in infants by targeted metabolomics. In our previous study, we showed that when FA is present in various phenotypes of AD in early life, it might be associated with the later development of asthma. The discovery of a biomarker that can distinguish the phenotypes that accompany AD and FA from other AD phenotypes is therefore expedient. Consequently, we aimed to investigate whether FA in AD infants. can be classified as gut sphingolipid metabolites using targeted metabolomics.
Institute
Asan Medical Center
Last NameYoo
First NameHyun Ju
Address88, Olympic-ro 43-gil, Songpa-gu
Emaild131108@ulsan.ac.kr
Phone0230104029
Submit Date2023-10-06
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2023-11-01
Release Version1
Hyun Ju Yoo Hyun Ju Yoo
https://dx.doi.org/10.21228/M8ZX5S
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001816
Project DOI:doi: 10.21228/M8ZX5S
Project Title:Gut sphingolipid metabolites in infants with atopic dermatitis associated with food allergy
Project Summary:This study determines S1P, ceradmides, sphingomyelins and diacylglycerols from infant feces to explore differential sphingolipid metabolism associated with food allergy in atopic dermatitis.
Institute:Asan Medical Center
Last Name:Yoo
First Name:Hyun Ju
Address:88, Olympic-ro, 43-gil, Songpa-gu, Seoul, Seoul, 05505, Korea, South
Email:yoohyunju@amc.seoul.kr
Phone:02-3010-4029

Subject:

Subject ID:SU003036
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:infant
Gender:Not applicable
Human Race:Pacific asian

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Factor
SA317395AD_22AD
SA317396AD_23AD
SA317397AD_21AD
SA317398AD_19AD
SA317399AD_18AD
SA317400AD_24AD
SA317401AD_20AD
SA317402AD_26AD
SA317403AD_30AD
SA317404AD_1AD
SA317405AD_29AD
SA317406AD_28AD
SA317407AD_27AD
SA317408AD_17AD
SA317409AD_25AD
SA317410AD_5AD
SA317411AD_7AD
SA317412AD_4AD
SA317413AD_3AD
SA317414AD_2AD
SA317415AD_11AD
SA317416AD_8AD
SA317417AD_6AD
SA317418AD_14AD
SA317419AD_15AD
SA317420AD_16AD
SA317421AD_12AD
SA317422AD_13AD
SA317423AD_10AD
SA317424AD_9AD
SA317425AD_FA_18AD_FA
SA317426AD_FA_17AD_FA
SA317427AD_FA_16AD_FA
SA317428AD_FA_19AD_FA
SA317429AD_FA_22AD_FA
SA317430AD_FA_15AD_FA
SA317431AD_FA_23AD_FA
SA317432AD_FA_21AD_FA
SA317433AD_FA_20AD_FA
SA317434AD_FA_6AD_FA
SA317435AD_FA_7AD_FA
SA317436AD_FA_5AD_FA
SA317437AD_FA_24AD_FA
SA317438AD_FA_8AD_FA
SA317439AD_FA_10AD_FA
SA317440AD_FA_13AD_FA
SA317441AD_FA_12AD_FA
SA317442AD_FA_9AD_FA
SA317443AD_FA_14AD_FA
SA317444AD_FA_40AD_FA
SA317445AD_FA_39AD_FA
SA317446AD_FA_38AD_FA
SA317447AD_FA_37AD_FA
SA317448AD_FA_36AD_FA
SA317449AD_FA_4AD_FA
SA317450AD_FA_41AD_FA
SA317451AD_FA_44AD_FA
SA317452AD_FA_43AD_FA
SA317453AD_FA_42AD_FA
SA317454AD_FA_35AD_FA
SA317455AD_FA_34AD_FA
SA317456AD_FA_28AD_FA
SA317457AD_FA_27AD_FA
SA317458AD_FA_26AD_FA
SA317459AD_FA_29AD_FA
SA317460AD_FA_30AD_FA
SA317461AD_FA_33AD_FA
SA317462AD_FA_32AD_FA
SA317463AD_FA_31AD_FA
SA317464AD_FA_25AD_FA
SA317465AD_FA_11AD_FA
SA317466AD_FA_57AD_FA
SA317467AD_FA_56AD_FA
SA317468AD_FA_55AD_FA
SA317469AD_FA_54AD_FA
SA317470AD_FA_58AD_FA
SA317471AD_FA_59AD_FA
SA317472AD_FA_62AD_FA
SA317473AD_FA_61AD_FA
SA317474AD_FA_60AD_FA
SA317475AD_FA_52AD_FA
SA317476AD_FA_51AD_FA
SA317477AD_FA_45AD_FA
SA317478AD_FA_2AD_FA
SA317479AD_FA_1AD_FA
SA317480AD_FA_3AD_FA
SA317481AD_FA_46AD_FA
SA317482AD_FA_47AD_FA
SA317483AD_FA_50AD_FA
SA317484AD_FA_49AD_FA
SA317485AD_FA_48AD_FA
SA317486AD_FA_63AD_FA
SA317487AD_FA_53AD_FA
SA317488AD_FA_79AD_FA
SA317489AD_FA_77AD_FA
SA317490AD_FA_76AD_FA
SA317491AD_FA_75AD_FA
SA317492AD_FA_80AD_FA
SA317493AD_FA_81AD_FA
SA317494AD_FA_83AD_FA
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 159

Collection:

Collection ID:CO003029
Collection Summary:The study population consisted of 158 six-month-old infants (46 healthy infants, 30 only AD group, and 82 with combined AD and FA) involved in the Cohort for Childhood Origin of Asthma and Allergic Diseases (COCOA) (reference: BMC Pulm Med 2014, 14:109.)
Sample Type:Feces

Treatment:

Treatment ID:TR003045
Treatment Summary:no treatment

Sample Preparation:

Sampleprep ID:SP003042
Sampleprep Summary:~10 mg of the freeze-dried feces was homogenized well with an internal standard solution (200 μl of 1 μM C17 S1P solution). Then, 300 μl of chloroform, 200 μl of methanol, 50 μl of H2O, and 10 μl of 10N NaOH were added to each solution, and vortex well. The aqueous layer was collected after centrifugation, where S1P was separated from other lipids under alkaline condition. 50 uL of H2O was added to the remaining solution and the aqueous layer was collected again after centrifugation. Then, S1P was re-extracted into the chloroform phase under acidic conditions using 400 μl of chloroform and 20 μl of 10M HCl. This step was repeated three times. The chloroform was evaporated, and the dried samples were reconstituted with methanol prior to LC-MS/MS analysis.

Combined analysis:

Analysis ID AN004793
Analysis type MS
Chromatography type Reversed phase
Chromatography system Thermo Dionex Ultimate 3000
Column Phenomenex Jupiter C4 (50 × 1.0 mm, 5um)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo LTQ XL
Ion Mode NEGATIVE
Units pmol/mg

Chromatography:

Chromatography ID:CH003624
Chromatography Summary:Ultimate 3000-gradient
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Phenomenex Jupiter C4 (50 × 1.0 mm, 5um)
Column Temperature:35
Flow Gradient:10% B for 0 min, 10–90% B for 5 min, 90% B for 10 min, 90–10% B for 0.1 min, and 10% B for 4.9 min
Flow Rate:300 μL/min
Solvent A:0.1% formic acid in H2O
Solvent B:0.1% formic acid in MeOH
Chromatography Type:Reversed phase

MS:

MS ID:MS004539
Analysis ID:AN004793
Instrument Name:Thermo LTQ XL
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Selected ion monitoring (SRM) was uesd in the negative ion mode and the extracted ion chromatogram corresponding to the specific transition (phosphate ion, PO3-, m/z 78.9585) for S1P was used for quantification. Calibration range was 0.01 – 10 μM with R2 > 0.99. Data analysis was performed by using Xcalibur 2.2 software. Ultimate3000
Ion Mode:NEGATIVE
  logo